Skip to content

King Pharmaceuticals KG European Hospital Liability — Year 1

Other product segments

All other lines
57%
International
41.8%
Commercial Auto Liability
11.9%
General Liability
5.9%

Similar metrics at other companies

Greenlight Capital RE, Ltd. logo
GLREFinancial — Year 1
28%-12.6pp
American International Group logo
AIGUK/Europe Property and Special Risks — Year 1 (as a percent)
20.1%-0.8pp
Greenlight Capital RE, Ltd. logo
GLREHealth — Year 1
114.6%0.0pp
CNA Financial logo
CNAMedical Professional Liability — Year 1
3.6%0.0pp
American International Group logo
AIGUK/Europe Casualty and Financial lines — Year 1 (as a percent)
5.3%-0.1pp
Axis Capital Holders logo
AXSInsurance — Year 1
29.5%

Other financials

Income statement

See full
Revenue$10.2M+1,112%
Net income-$7.4M-1,786%
EPS (diluted)-$0.96-586%

Balance sheet

See full
Cash & equivalents$62.2M+1,724%
Total debt$176.7M
Total equity$121.4M+2,773%
Total assets$964.2M

Cash flow

See full
Operating cash flow-$15.1M-1,628%

Valuation

See full
Market cap$70.42M-67.6%
Enterprise value$184.93M-50.0%
P/E1.2×
P/S1.6×-24.3×

Profitability

See full
Net margin131.5%

Returns & leverage

See full
Return on equity90.8%
Debt / equity1.5×

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShortdurationInsuranceContractsHistoricalClaimsDurationYearOne.

The official record: King Pharmaceuticals’s 10-K, filed March 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's european hospital liability — year 1.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is King Pharmaceuticals's european hospital liability — year 1?
King Pharmaceuticals (KG) reported european hospital liability — year 1 of 3.2% in Q4 2025.
What does european hospital liability — year 1 mean?
This metric represents the development of claims or financial performance specifically for the first year of the underwriting cycle within the European Hospital Liability segment. It is used to analyze the initial loss emergence patterns and the accuracy of early-stage actuarial estimates for this product line.